(Stock Code: 1177.HK)
2025 2025 Interim Results Announcement2025.8.18 Hong Kong
CONTENTS
Financial Highlights Pipeline Highlights
2
Financial Highlights
Both revenue and profit achieved double-digit growth
(RMB bn)
10.7%
2024 H1
Continuing Operations
2025 H1
Continuing Operations
Revenue
15.87
17.57
140.2%
2024 H1
Continuing Operations
2025 H1
Continuing Operations
Profit attributable to owners of the parent
(as reported)
1.41
3.39
101.1%
2024 H1
Continuing Operations
2025 H1
Continuing Operations
Profit attributable to owners of the parent
(underlying profit)1)
1.54
3.09
Notes 1 Profit attributable to owners of the parent (underlying profit): which is 'adjusted non-HKFRS attributable earnings' and is presented as an additional financial measure to provide supplementary information for 3
better assessment of the performance of Sino Biopharm's core operations. Sino Biopharm is committed to maintaining the stability of this adjustment basis for investors' reference. Please refer to the next page fo r details.
Profit attributable to owners of the parent (underlying profit)
(RMB bn)
2025H1
2024H1
Growth
Profit attributable to owners of the parent (as reported) 3.39 3.02 +12.3%
Profit attributable to the owners of the parent from discontinued operations
-
-1.61
Share of profits and losses of associates and joint ventures (net of related tax and non-controlling interests)
0.00 0.09
Fair value changes and the impairment of one-off adjustments of certain assets and liabilities (net of related tax and non-controlling interests)
-0.33
0.05
Fair value losses/(gains) of current equity investments, net (net of related tax and non-controlling interests)
0.01 -0.01
Share-based payment (net of related tax and non-controlling interests)
0.02
-
Convertible bond debt component of:
Effective interest expenses | 0.00 | 0.00 | |
Exchange loss/(gain) | 0.00 | -0.00 | |
Profit attributable to owners of the parent (underlying profit) | 3.09 | 1.54 | +101.1% |
Notes 1 Profit attributable to owners of the parent (underlying profit): which is 'adjusted non-HKFRS attributable earnings' 4
Innovative Products
Achieved 27.2% growth, products launched in 2023-2025 ramped up rapidly
Revenue from innovative products
Revenue from innovative products
Revenue from innovative products, as a % of total revenue
44.4%
38.6%
27.2%
7.80
6.13
2024 H1
Continuing Operations
2025 H1
Continuing Operations
(RMB bn)
Anbeisi ( ®)
Bevacizumab Injection
Delituo ( ®)
Rituximab Injection
Saituo
Anhengji
(
®)
(
Efbemalenograstim alfa Injection
Trastuzumab for Injection
®)
rhFVIII
for Injection
Andewei
Anfangning
( ®) ( ®) (
Anboni
®)
Anluoqing
(
®)
Paletan ( ®)
Beilelin ( ®)
Benmelstobart Garsorasib Unecritinib Fumarate Envonalkib Pertuzumab Liraglutide Injection Tablet Capsules Citrate Capsules injection Injection
Putaning ( ®)
Anqixin ( ®)
Meloxicam Injection (II)
rhFVIIa N01 for Injection
NDA submitted
Culmerciclib TQB3616
(CDK2/4/6 inhibitor)
NDA submitted
Zongertinib BI 181063
(HER2 inhibitor)
Notes 1 Innovative products include innovative drugs and biosimilars 5